Novel antifungal agents in clinical trials

Antiangiogenic strategies and agents in clinical trials.

The understanding that the growth of tumors depends on the acquisition of a blood supply has led to the development of new therapies for cancer and other angiogenic diseases based on inhibition of neovascularization. This review examines the role of angiogenesis in cancer progression and describes various strategies for interfering with this process. The developmental status of angiogenesis inh...

Clinical Trials of Antifungal Prophylaxis in Surgical Critically Ill Patients

Antifungal Agents

Continued advancement of medical science offers life-saving treatment options for a variety of hematologic, oncologic, and rheumatologic conditions. Immunosuppression, a common therapeutic side-effect, predisposes patients to invasive fungal infections, which are escalating in prevalence. The development of effective, welltolerated antifungals has lagged behind the advances of antibacterial the...

Evaluation of Clinical Trials

In a number of important clinical issues such as evaluation of the efficacy or effectiveness of therapeutic or preventive interventions as well as for comparing the harms of interventions, randomized controlled trials (RCTs) provide the highest levels of evidence, either directly or indirectly. It is obvious that critical appraisal of these studies to assess their validity and precision is of p...

Green Chemical Synthesis and Biological Evaluation of Novel N-substituted Rhodanine Derivatives as Potential Antifungal Agents

Background and purpose: In medicinal chemistry, molecules containing rhodanine(2-thiazolidine-4-one) ring as a magic multifunctional privileged structural and functional scaffold show a broad range of potent pharmacological properties containing anti-microbial, antiviral, anti-diabetic, and anti-convulsant effects. Evidence suggests that the activity of the rhodanine derivative correlates with ...